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Introduction: To assess the safety and immunogenicity of MAGE-A3 
immunotherapeutic in patients with stage IB–III MAGE-A3-positive 
non–small-cell lung cancer (NSCLC) who were or were not undergo-
ing standard cisplatin/vinorelbine chemotherapy.
Methods: This open, prospective, multicenter, parallel-group phase I 
study (NCT00455572) enrolled patients with resected (cohorts 1–3) 
or unresectable (cohort 4) MAGE-A3-positive NSCLC. MAGE-A3 
immunotherapeutic (300 μg recombinant MAGE-A3 formulated 
with AS15) was administered (eight doses, 3 weeks apart) concur-
rent with (cohort 1), after (cohort 2), or without (cohort 3) stan-
dard-adjuvant chemotherapy, or after standard radiotherapy and/or 
chemotherapy (cohort 4).
Results: Sixty-seven patients received greater than or equal to 1 
dose of MAGE-A3 immunotherapeutic. Grade 3/4 adverse events 
(AEs) were reported for 16 out of 19 (84%), 2 out of 18 (11%), 5 
out of 18 (28%), and 1 out of 12 (8%) patients in cohorts 1, 2, 3, 
and 4, respectively. Many grade 3/4 AEs in cohort 1 (e.g., neutrope-
nia) were typical of chemotherapy. Six patients, including three in 
cohort 1, reported study treatment–related grade 3/4 AEs (injection-
site reactions or musculoskeletal/back pain, which resolved within 5 
days). One patient (in cohort 4) died, but this and the other serious 
adverse events were not study treatment related. MAGE-A3-specific 
antibody responses to immunotherapy were induced in all patients 
evaluated in all cohorts. MAGE-A3-specific CD4+ T-cell responses 
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to immunotherapy were detected in 4 out of 11 (36%), 4 out of 15 
(27%), 2 out of 8 (25%), and 5 out of 6 (83%) evaluated patients in 
cohorts 1, 2, 3, and 4, respectively; and CD8+ T-cell responses were 
only detected in four patients.
Conclusion: In resected and unresectable NSCLC patients and irre-
spective of whether standard chemotherapy was concurrent or not, 
MAGE-A3 immunotherapeutic is well tolerated and induces MAGE-
A3-specific immune responses.
Key Words: Adjuvant chemotherapy, Immunotherapy, Immunostimulant, 
MAGE-A3, Non–small cell lung carcinoma, Vaccine
(J Thorac Oncol. 2015;10: 1458–1467)
Non–small-cell lung cancer (NSCLC) represents approxi-mately 85% of all lung cancer cases.1,2 Complete resec-
tion is the mainstay of treatment for early (stage I and II) and 
some locally advanced (stage IIIA) NSCLC. The major limita-
tion remains recurrence of disease, with 5-year survival rang-
ing between 73% (stage IA) and 24% (stage IIIA).3
Chemotherapy with cisplatin (CDDP)-based doublets is 
the standard treatment after surgery for stage IIA–IIIA NSCLC 
with an absolute 5-year survival benefit of 5.4%.4,5 The absolute 
5-year survival benefit for CDDP and vinorelbine (VNR) che-
motherapy has been estimated at greater than or equal to 8.6%.6,7 
However, the lung adjuvant cisplatin evaluation (LACE) meta-
analysis did not identify a survival benefit for CDDP-based 
adjuvant chemotherapy in stage IB disease,5 although a sur-
vival benefit was suggested for patients with large tumors in the 
CALGB9633 study.8 Hence, the efficacy of adjuvant chemother-
apy remains limited and only for selected patients. For unresect-
able stage III NSCLC, platinum-based chemotherapy combined 
with thoracic radiotherapy remains a recommended treatment 
and provides marginal 5-year survival benefit over radiotherapy 
alone.9–11 Therefore, even with these advances, new approaches 
are required to improve the prognosis for NSCLC patients.
Cancer immunotherapy represents a different approach 
and encompasses a broad range of strategies to induce or boost 
immune-mediated tumor-cell destruction (active immunother-
apy), or to counteract mechanisms by which tumor cells evade or 
suppress immune-mediated destruction (passive immunother-
apy).12–16 Several different strategies have entered late-stage clin-
ical development,12,16,17 including active immunotherapies18–23 
and immune-checkpoint inhibitors.24–26 Immune-checkpoint 
inhibitors include the anticytotoxic T lymphocyte-associated 
antigen (CTLA-4), and programmed death receptor-1 (PD-1), 
and anti-PD-L1 compounds. These compounds target tumor- 
mediated inhibition of cytotoxic T-cell activity; preliminary 
evidence for these compounds being administered as monother-
apies or in combination with chemotherapy or targeted agents 
has revealed promising activity with manageable toxicity.27,28
MAGE-A3 cancer immunotherapeutic is an active 
immunotherapy that has been evaluated in NSCLC and 
melanoma patients.29–32 It contains recombinant full-length 
MAGE-A3 protein formulated with the immunostimulant 
AS15. MAGE-A3 is a cancer/testis antigen33 and is considered 
to be tumor-specific because the only normal cells (spermato-
gonia and trophoblasts) in which it is expressed are unable to 
present MAGE-A3 epitopes because of the absence of class 
I and II human leukocyte antigens.34–38 MAGE-A3 expression 
has been identified in 24% to 45% of NSCLCs (stages I–IV) 
and seems relatively more prevalent in squamous cell carcino-
mas than in other histological types.36,39,40
The intention of combining active immunotherapy with 
radiotherapy and/or chemotherapy would be to provide additive 
or synergistic clinical benefits without jeopardizing schedule and 
dosage of standard chemotherapies or radiotherapies. Moreover, 
the earlier administration of active immunotherapy, that is, 
concurrent with rather than after chemotherapy, would permit 
the earlier development of an immune response. Theoretically, 
chemotherapy or radiotherapy may increase the susceptibility 
of residual tumor cells to immune-mediated attack by inhibit-
ing regulatory-T cells or by invoking stress or immunogenic 
cell death responses in the same tumor cells and resulting in the 
exposure/release of tumor-associated antigens and the potential 
for tumor-antigen spreading.41–45 Conversely, chemotherapy, and 
corticosteroids often used concurrently as antiemetics, may det-
rimentally affect the response to active immunotherapy through 
their potentially immunosuppressive side-effects.46 Therefore, 
the objective of this phase I study was to evaluate, in patients 
with MAGE A3-positive NSCLC, the safety and immunoge-
nicity (MAGE-A3-specific T-cell and antibody responses) 
of MAGE-A3 immunotherapeutic in different treatment set-
tings that do or do not include chemotherapy. Two of the four 
treatment settings were also evaluated in the concurrently per-
formed MAGE-A3 as Adjuvant Non-Small Cell LunG CanceR 
ImmunoTherapy (MAGRIT) trial initiated in October 2007.31
PATIENTS AND METHODS
Study Design
The clinical study (NCT00455572) was an open, non-
randomized phase I/II study conducted at 18 centers in five 
European countries (Belgium, France, Germany, Italy, and 
United Kingdom) and Canada. The study was conducted in 
accordance with good clinical practice guidelines and all 
applicable regulatory requirements, including the Declaration 
of Helsinki (1996). The protocol was approved by the review 
boards at all participating institutions, and all patients gave 
written informed consent.
Eligible patients had pathological stage IB, II, or III (but 
not III/N2–347) NSCLC, which was MAGE A3-positive (deter-
mined by reverse-transcriptase polymerase chain reaction [PCR] 
on paraffin-embedded primary tumor sample; Supplementary 
Methods, Supplemental Digital Content 1, http://links.lww.
com/JTO/A890). Patients had adequate bone-marrow reserve 
and renal and hepatic function (Supplementary Methods, 
Supplemental Digital Content 1, http://links.lww.com/JTO/
A890). In patients with resected tumors, resection was anatom-
ical, involving at least a lobe and with a level of lymph node 
sampling corresponding to the standard procedures at the cen-
ter (Supplementary Methods, Supplemental Digital Content 1, 
http://links.lww.com/JTO/A890). Patients who had concomi-
tant or previous malignancies at other sites (unless the malig-
nancy had been effectively treated), history of anaphylaxis or 
severe allergic reaction; concurrent severe medical problems, 
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psychiatric or addictive disorders, and patients who required con-
comitant treatment with systemic corticosteroids, or any other 
immunosuppressive agents were not eligible (Supplementary 
Methods, Supplemental Digital Content 1, http://links.lww.com/
JTO/A890, for other standard eligibility criteria).
Patients with resected tumors were entered into cohort 
1, standard CDDP/VNR chemotherapy concurrently delivered 
with MAGE-A3 immunotherapeutic; cohort 2, chemotherapy 
(≥2 cycles) before MAGE-A3 immunotherapeutic; or cohort 3, 
MAGE-A3 immunotherapeutic only. Patients with unresectable 
stage III tumors were entered into cohort 4, chemotherapy (≥2 
cycles) and radiotherapy before MAGE-A3 immunotherapeu-
tic. Patients in cohort 1 or 2 had Eastern Cooperative Oncology 
Group scores less than or equal to 1 at screening, whereas patients 
in cohort 3 or 4 had Eastern Cooperative Oncology Group scores 
less than or equal to 2 at screening. Patients in cohort 4 had stable 
disease or objective responses (confirmed by computed tomogra-
phy scan) after standard radiotherapy/chemotherapy.
Study Treatment
The treatment plan included eight doses (3 weeks apart) 
of MAGE-A3 immunotherapeutic (the study treatment; GSK 
Vaccines, Rixensart, Belgium; Fig. 1A). The first dose was 
within 4 to 12 weeks after resection (cohorts 1 and 3), 2 to 4 
weeks after adjuvant chemotherapy (cohort 2), or 2 to 6 weeks 
after radiotherapy/chemotherapy (cohort 4). In cohort 1, the first 
four doses of MAGE-A3 immunotherapeutic and chemotherapy 
were administered concurrently, with MAGE-A3 immuno-
therapeutic being administered on day 8 of each chemotherapy 
cycle. In cohort 2, MAGE-A3 immunotherapeutic was adminis-
tered 2 to 4 weeks after completion of all chemotherapy cycles. 
Chemotherapy consisted of four consecutive cycles, at 3-week 
intervals: CDDP (80 mg/m2) on day 1; VNR (30 mg/m2) on days 
1 and 8 (Supplementary Methods, Supplemental Digital Content 
1, http://links.lww.com/JTO/A890, for dose modification rules 
for chemotherapy). MAGE-A3 immunotherapeutic was injected 
intramuscularly (one dose = 0.5 ml) in the deltoid or lateral 
region of the thigh, alternating left and right side for subsequent 
doses. MAGE-A3 immunotherapeutic contained recombinant 
MAGE-A3 protein (300 µg)48 and GSK’s proprietary immunos-
timulant, AS15 (Supplementary Methods, Supplemental Digital 
Content 1, http://links.lww.com/JTO/A890. for the preparation 
of MAGE-A3 immunotherapeutic for injection).
Endpoints
The safety endpoints were the occurrence of adverse 
events (AEs), including abnormal hematological and bio-
chemical laboratory values and potential immune-mediated 
disorders, and serious adverse events (SAEs), primarily from 
the first dose to 30 days after the last dose of the MAGE-A3 
immunotherapeutic. The immunogenicity endpoints were 
MAGE-A3-specific antibody seropositivity and T-cell 
responses to treatment primarily after the fourth dose.
Safety Assessment
All AEs including SAEs were evaluated by the investiga-
tor and were categorized according to Medical Dictionary for 
Regulatory Activities (MedDRA) terminology (version 12.0; 
MedDRA MSSO, McLean, VA). Each AE/SAE was graded for 
intensity according to the International Common Terminology 
Criteria for Adverse Events (CTCAE; version 3.0; National 
Cancer Institute, Bethesda, MD) and was assessed for its rela-
tionship with the MAGE-A3 immunotherapeutic treatment. 
SAEs were identified in accordance with the standard defini-
tion (Supplementary Methods, Supplemental Digital Content 
1, http://links.lww.com/JTO/A890).
Immunogenicity Assessments
MAGE-A3-specific antibody concentrations were deter-
mined using an adapted enzyme-linked immunosorbent assay 
methodology32 with reference to a standard curve of positive 
control samples (values are reported as enzyme-linked immu-
nosorbent assay units per milliliter). Peroxidase-linked anti-
human IgG (CAPPEL Inc., PA) was used to detect antibodies 
bound to recombinant MAGE-A3 antigen. Seropositivity was 
defined as an antibody concentration greater than or equal to 27 
enzyme-linked immunosorbent assay units per milliliter, and a 
humoral response to treatment defined by seroconversion or by 
greater than or equal to twofold increase in concentration com-
pared with pretreatment. MAGE-A3-specific CD4+ and CD8+ 
T-cell responses were assessed by in vitro peptide-stimulation 
of peripheral blood mononuclear cells (PBMCs) using intra-
cellular-cytokine staining and flow cytometry. Frozen stocks 
of PBMCs were prepared from blood samples using routine 
procedures. For each sample, freshly thawed PBMCs were 
seeded (2 × 105 cells/round-bottom well, in a 96-well plate) 
into 24 wells and incubated in culture medium (Roswell Park 
Memorial Institute medium plus 10% horse serum) supple-
mented with interleukin-2 (10 IU/ml) and interleukin-7 (20 ng/
ml) and containing a peptide pool (15 mers with 10 amino-acid 
overlaps) spanning the entire sequence of MAGE-A3 protein at 
1 µg/ml/peptide. A predefined cutoff of less than 60% viability 
invalidated a thawed PBMC sample for further analysis. Each 
well was split in two on day 7, pooled back down to 12 wells 
on day 13. On day 14, each well was split in two, and 12 wells 
were incubated for 6 hours with the culture medium containing 
the peptide pool (test), and the other 12 duplicate wells were 
incubated with the culture medium without the peptide pool 
(control); with Brefeldin A being added after 2-hour incuba-
tion. Intracellular cytokine staining was performed with the fol-
lowing antibodies anti-CD3PercP, anti-CD4PE-cy7, anti-CD8APC-cy7, 
anti-interferon (anti-IFN)-γFITC, and anti-tumor necrosis fac-
torPE (anti-TNFPE), and fluorescence-activated cell sorting was 
then used to detect and enumerate CD4+ or CD8+ T cells that 
were also IFN-γ+ TNF-α+ (at least 3000 T cells were required 
to validate the well). A ratio of the percentages of IFN-γ+ TNF-
α+ (CD4+ or CD8+) T cells/all (CD4+ or CD8+) T cells in the 
peptide-stimulated (test) well versus the peptide-unstimulated 
(control) well was calculated for each pair of duplicate wells. 
A T-cell immunogenicity score was determined as the geomet-
ric mean of the ratios in the pairs of duplicate wells. A PBMC 
sample was valid when at least 7 of 12 of these ratios were used 
to determine the T-cell immunogenicity score. A MAGE-A3-
specific (CD4+ or CD8+) T-cell response was identified if the 
patient’s T-cell immunogenicity score was above the cut-off 
score (CD4+ = 8.4; or CD8+ = 3.2). The cut-off scores were 
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FIGURE 1.  A, Study design. B, The allocation and participation of patients during the course of the study. A, The treatment 
plan included eight doses (3 weeks apart) of MAGE-A3 cancer immunotherapeutic (CI). In cohort 1, CI was integrated into 
the chemotherapy (CT) treatment schedule such that the first four doses of CI were administered on the eighth day of each of 
the four chemotherapy cycles. B, All patients in the total treated population (TTP) were included for the analyses of safety. The 
reasons for withdrawal from the study are described to the left. *Note that this one patient in cohort 3 received the full eight-
dose regimen but did not attend the concluding visit. Note that the three “other” reasons for withdrawal in cohort 1 included 
reduced compliance, the diagnosis of a different type of cancer, and a comorbidity related to a suspected cytochrome poly-
morphism. Cohort 1, concurrent chemotherapy + immunotherapy; cohort 2, sequential chemotherapy then immunotherapy; 
Cohort 3, immunotherapy only; Cohort 4 (unresectable non–small-cell lung cancer), sequential chemotherapy, radiotherapy, 
then immunotherapy.
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derived using the same methodology but with PBMCs from 
24 healthy Caucasian donors; and calculated as the upper 95th 
percentile of 24 T-cell immunogenicity scores. A MAGE-A3-
specific T-cell response to treatment was identified if the T-cell 
immunogenicity score postdose 4 or postdose 8 was above the 
cutoff and was greater than or equal to fourfold higher than 
pretreatment.
Statistics
This was the first study of MAGE-A3 immunothera-
peutic in a target population of MAGE A3-positive NSCLC 
patients who were receiving, or had recently received, che-
motherapy after tumor resection. The sample size was, there-
fore, typical of studies of this kind and was based on general 
experience rather than any formal estimate or hypothesis. It 
was anticipated that out of 18 patients enrolled in a cohort, 15 
patients would be evaluated for immunogenicity. Appropriate 
descriptive statistics were applied to demographic and other 
baseline characteristics. SAS (version 9.2, SAS Institute Inc. 
Cary, NC) was used for all computations.
RESULTS
Patients and Treatment
From May 2007 to February 2013, 428 patients were 
screened. Of those patients with available and valid tumor-
PCR results, 33% (106/320) had MAGE-A3-positive tumors. 
From those 106 patients, 71 were enrolled in cohorts 1, 2, 3, 
and 4 (23, 18, 18, and 12, respectively; Fig. 1). Sixty-seven 
patients received at least one dose of MAGE-A3 immunothera-
peutic (19, 18, 18, and 12 in cohorts 1, 2, 3, and 4, respectively) 
and were included in the total treated population, in which the 
study endpoints were evaluated.
Patients were aged from 37 to 81 years (median 61 
years; Table 1). The majority of patients were male (78%). 
As expected, more patients in cohort 3 (12/18) had stage IB 
tumors than in cohorts 1 (3/19) and 2 (3/18).
All patients in cohorts 2 and 4 received at least two 
cycles of prior chemotherapy. All patients in cohort 4 except 
one received prior radiotherapy. The full eight doses of 
MAGE-A3 immunotherapeutic were received by 46 out of 67 
(69%) patients. These included 15 out of 19 (79%), 14 out of 
18 (78%), 9 out of 18 (50%), and 8 out of 12 (68%) patients in 
cohorts 1, 2, 3, and 4, respectively (Fig. 1). In cohort 1, 16 out 
of 19 (84%) patients received at least two cycles of concomi-
tant chemotherapy and for those who completed the study, 9 
out of 15 (60%) received the full 80 mg/m2 doses of CDDP, 
and 1 out of 15 (7%) received carboplatin instead of CDDP. 
The largest dose reduction of CDDP was by 25% to 60 mg/m2, 
which occurred in 2 out of 15 (13%) patients.
The most frequent reason for early discontinuation from 
the study was the recurrence of disease, and this occurred 
in cohort 2 (4/18; 22%), cohort 3 (6/18; 33%), and cohort 
4 (3/12; 25%), but not in cohort 1 (Fig. 1B). Other reasons 
for discontinuations included one patient who died (cohort 4; 
because of a bronchial hemorrhage); two patients who with-
drew because of treatment-unrelated SAEs (cohorts 1 and 3; 
pneumonia and cardiac failure, respectively); one patient who 
withdrew because of a nonserious AE (cohort 3; influenza-
like illness); one patient who withdrew consent (cohort 3); 
one patient who was lost to follow-up (cohort 3); and three 
patients who withdrew for other reasons (cohort 1; Fig. 1).
Safety
All patients in cohorts 1 and 2 and most patients in 
cohort 3 (17/18; 94%) and cohort 4 (11/12, 92%) reported 
AEs (Table 2 and Fig. 2). Most patients (67–94%) in each 
cohort reported AEs in the general disorders and administra-
tion site conditions category. In cohort 1, 14 out of 19 (74%) 
patients reported gastrointestinal disorders (mainly nausea, 
TABLE 1.  Patient Characteristics
All Cohort 1 Cohort 2 Cohort 3 Cohort 4
Enrolled patients 71 23 18 18 12
TTP 67 19 18 18 12
Median age (range), yr 61 (37–81) 59 (37–75) 61 (47–69) 68 (51–81) 62 (48–73)
Sex (%) Female 15 (22) 5 (26) 3 (17) 2 (11) 5 (42)
Male 52 (78) 14 (74) 15 (83) 16 (89) 7 (58) 
ECOG performance status 0 23 3 8 4 8
1 43 16 10 13 4
2 1 0 0 1 0
Stage Stage IB 18 3 3 12 0
Stage II (IIA, IIB) 17 (3, 14) 6 (1, 5) 9 (2, 7) 2 (0, 2) 0
Stage III (IIIA, IIIB) 32 (21, 11) 10 (9, 1) 6 (5, 1) 4 (3, 1) 12 (4, 8)
Histology type Squamous 29 9 10 9 1
Nonsquamous 38 10 8 9 11
Type of surgery Lobectomy 42 13 13 16 0
Pneumonectomy 13 6 5 2 0
Cohort 1, concurrent chemotherapy + immunotherapy; cohort 2, sequential chemotherapy then immunotherapy; cohort 3, immunotherapy only; cohort 4 (unresectable NSCLC), 
sequential chemotherapy, radiotherapy, then immunotherapy; NSCLC, non–small-cell lung cancer; TTP, total treated population.
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constipation, vomiting, and diarrhea) and 14 out of 19 (74%) 
patients reported blood and lymphatic disorders (mainly 
neutropenia and anemia), whereas in cohorts 2, 3, and 4, 8 
out of 18 (44%), 6 out of 18 (33%), and 3 out of 12 (25%) 
patients, respectively, reported gastrointestinal disorders, and 
no patients reported blood and lymphatic disorders (Fig. 2). 
Moreover, in cohort 1, most (33/39, 85%) of the gastrointesti-
nal disorders and all (28/28, 100%) of the blood and lymphatic 
FIGURE 2.  The number of patients reporting adverse events (AEs) from the first dose to 30 days after the last dose of the 
MAGE-A3 immunotherapeutic, categorized by MedDRA System Organ Class, in the total treated population (TTP). For a patient 
reporting an AE with the same System Organ Class on more than one occasion, only the highest graded AE is indicated. Note 
that the category general disorders and administration site conditions includes the preferred terms; administration site pain, 
administration site reaction, asthenia, chills, fatigue, gait disturbance, hypothermia, influenza-like illness, injection-site cold-
ness, injection-site erythema, injection-site hematoma, injection-site inflammation, injection-site oedema, injection-site pain, 
injection-site pruritus, injection-site rash, injection-site reaction, injection-site swelling, malaise, mucosal inflammation, pyrexia, 
and sense of oppression. Cohort 1, concurrent chemotherapy + immunotherapy; cohort 2, sequential chemotherapy then 
immunotherapy; cohort 3, immunotherapy only; cohort 4 (unresectable non–small-cell lung cancer), sequential chemotherapy, 
radiotherapy, then immunotherapy.
TABLE 2.  Summary of Patient Numbers Reporting AEs/SAEs from the First Dose to 30 Days After the Last Dose of the 
MAGE-A3 Immunotherapeutic
Adverse Events
Cohort 1 
(N = 19), n (%)
Cohort 2 
(N = 18), n (%)
Cohort 3 
(N = 18), n (%)
Cohort 4 
(N = 12), n (%)
Any All grades 19 (100) 18 (100) 17 (94) 11 (92)
Grade 3 5 (26) 2 (11) 3 (17) 1 (8)
Grade 4 11 (58) 0 2 (11) 0
Grade 5 0 0 0 1 (8)
SAEsa 14 (74) 0 4 (22) 3 (25)
Related to CI treatment All grades 14 (74) 17 (94) 16 (89) 7 (58)
Grade 3 3 (16) 1 (6) 2 (11) 0
Grade 4 0 0 0 0
Grade 5 0 0 0 0
SAEs 0 0 0 0
aTwo patients in cohort 1 and one patient in Cohort 3 reported SAEs that occurred during the study period but either before the first MAGE-A3 immunotherapeutic dose or more 
than 30 days after the last MAGE-A3 immunotherapeutic dose.
AEs, adverse events; SAEs, serious adverse events; CI, cancer immunotherapeutic; cohort 1, concurrent chemotherapy + immunotherapy; cohort 2, sequential chemotherapy then 
immunotherapy; cohort 3, immunotherapy only; cohort 4 (unresectable NSCLC), sequential chemotherapy, radiotherapy, then immunotherapy; NSCLC, non–small-cell lung cancer.
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disorders were reported during the phase when chemotherapy 
was concomitant with immunotherapy (i.e., up to 7 days after 
MAGE-A3 immunotherapeutic dose 4) and were typical reac-
tions to chemotherapy.
One grade 5 AE, the fatal bronchial hemorrhage (unre-
lated to study treatment), occurred 20 days after dose 1 in cohort 
4. Grade 3/4 AEs were reported for 16 out of 19 (84%), 2 out of 
18 (11%), 5 out of 18 (28%), and 1 out of 12 (8%) patients in 
cohorts 1, 2, 3, and 4, respectively (Table 2). The most frequent 
of these grade 3/4 AEs in cohort 1 was neutropenia. No other 
abnormal laboratory values were reported during the study.
Study treatment–related AEs were graded 1 to 3 (mostly 
1 or 2) and reported for 14 out of 19 (74%), 17 out of 18 
(94%), 16 out of 18 (89%), and 7 out of 12 (58%) patients in 
cohort 1, 2, 3, and 4, respectively (Table 2). Most of the gen-
eral disorders and administration site conditions were study 
treatment related. Other categories of related AEs (eg, gastro-
intestinal, nervous system) were only reported for a minority 
of patients (≤4) in each cohort. The related grade 3 AEs were 
reported for 3 out of 19 (16%), 1 out of 18 (6%), and 2 out of 
18 (11%) patients in cohorts 1, 2 and 3, respectively, and all 
resolved within 5 days. These AEs were injection-site related 
or musculoskeletal/back pain. No related grade 3 AEs were 
reported in cohort 4.
Thirty-six SAEs were reported for 21 patients: 28 SAEs 
for 14 out of 19 (74%) patients in cohort 1, 5 SAEs for 4 
out of 18 (22%) patients in cohort 3, and 3 SAEs, including 
the fatal one, for 3 out of 12 (25%) patients in cohort 4. No 
patients reported a SAE in cohort 2. No SAE was study treat-
ment related. Thirty-one SAEs were graded 3 or above.
One potential immune-mediated disorder, a grade 1 
Raynaud’s phenomenon considered as study treatment unre-
lated, was reported 19 days postdose 2 for a patient in cohort 1.
Immunogenicity
Immunogenicity results were not obtained from all 
patients because of missing or invalid samples. Before immu-
notherapy, 6 out of 65 patients (9%) were seropositive for 
MAGE-A3-specific antibodies and were in cohort 1 (1/19, 5%), 
cohort 2 (4/18, 22%), and cohort 4 (1/12, 8%), but not in cohort 
3 (0/16). After dose 4, all patients evaluated were seropositive 
(12, 15, 12, and 9 patients in cohorts 1, 2, 3, and 4 respectively; 
Fig. 3A) and were humoral responders to immunotherapy.
Before immunotherapy, MAGE-A3-specific CD4+ 
T-cell responses were detected in 5 out of 49 (10%) patients: 
23% (3/13), 6% (1/17) 0% (0/11), and 12% (1/8) patients in 
cohorts 1, 2, 3, and 4, respectively. MAGE-A3-specific CD8+ 
T-cell responses were detected in 2 out of 49 patients (5%), 
both of whom were in cohort 2 (i.e., 2/17, 6%). Out of these 
seven patients in whom T-cell responses were detected, only 
one patient was also antibody seropositive.
After dosing, MAGE-A3-specific CD4+ T-cell responses 
to immunotherapy were induced in 36% (4/11), 27% (4/15), 
25% (2/8), and 83% (5/6) patients in cohorts 1, 2, 3, and 
4, respectively (Fig. 3B). MAGE-A3-specific CD8+ T-cell 
responses to immunotherapy were induced in four patients; 1 
out of 11 (9%) in cohort 1, 1 out of 15 (7%) in cohort 2, 0 out 
of 8 (0%) in cohort 3, and 2 out of 6 (33%) in cohort 4.
DISCUSSION
Historically, the potential immunosuppressive activity of 
chemotherapy, and its use with antiemetic corticosteroids, has 
been viewed as a barrier for its use in combination with immu-
notherapy.46 However, recent evidence has suggested that che-
motherapy and/or radiotherapy may promote immune-mediated 
tumor destruction suggesting potential synergistic actions with 
immunotherapy.41,46,49 In this study, the immunogenicity and 
safety of MAGE-A3 immunotherapeutic treatment in stage IB 
to III NSCLC patients seemed not to be detrimentally affected 
by concurrent or prior CDDP/VNR-based chemotherapy or 
prior radiotherapy, supporting the use of MAGE-A3 immu-
notherapeutic in the chemotherapy and radiotherapy settings. 
Although patients were recruited from many centers in Europe 
and Canada, the strength and generalizability of the conclu-
sions are limited by the study design: a nonrandomized trial of 
a small patient population without inferential statistics.
The safety profile of the MAGE-A3 immunotherapeu-
tic treatment was in line with what has been observed with 
previous studies, with mainly grade 1/2 AEs categorized as 
general disorders and administration site conditions and typi-
cal of immunization.29,30 Grade 3/4 AEs were only frequently 
observed in cohort 1 and were typical of chemotherapy (eg, 
neutropenia).6 The tolerance to chemotherapy in cohort 1 
seemed unaffected by the concurrently administered immu-
notherapy probably reflecting the different modes of action of 
the two treatments.
Before immunotherapy, a small minority of patients dis-
played MAGE-A3-specific immune responses (9% antibody, 
10% CD4+ T cell, and 5% CD8+ T cell) in line with a previ-
ous study where 9% patients were seropositive.30 Therefore, 
although the tumors were MAGE-A3 positive by reverse-tran-
scriptase PCR, this positive expression had not necessarily 
translated into a spontaneous immune response. No associa-
tion was identified between seropositivity and cell-mediated 
immune reactivity. Yet there was the suggestion that the prior 
chemotherapy or radiotherapy administered in cohorts 2 and 
4 had elevated the pretreatment frequency of seropositive 
patients to 17% (6/30) compared with the other adjuvant-
setting cohort (5%, 1/19) and to the detection of MAGE-A3-
specific CD8+ T-cell responses in cohort 2.
After four doses of MAGE-A3 immunotherapeutic, 
MAGE-A3-specific antibody responses to immunotherapy 
were detected in all patients. Although MAGE-A3-specific 
antibodies may not directly be involved in eradicating tumor 
cells, they may contribute; because antibody-mediated opso-
nization of MAGE-A3 has been found to promote cross-pre-
sentation to naïve T cells.50 This potential mechanism may 
be relevant if MAGE-A3 is released during chemotherapy-
related immunogenic tumor-cell death.41
MAGE-A3-specific CD4+ T-cell responses to immu-
notherapy were detected in 29% (10/34) of patients with 
resected tumors (cohorts 1–3) and in 83.3% of patients with 
unresectable tumors (cohort 4). The corresponding CD8+ 
T-cell responses to immunotherapy were 6% (2/34; cohorts 
1–3) and 33% (cohort 4). The higher prevalence and magni-
tude of these responses in cohort 4 suggested that the pres-
ence of tumor tissue combined with its prior exposure to 
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radiotherapy/chemotherapy (potentially promoting immu-
nogenic-cell death) may have supported the development of 
T-cell responses to immunotherapy.41,43,44
In the recent placebo-controlled MAGRIT phase III 
trial,31 the treatment of stage IB, II, and IIIA NSCLC patients 
with MAGE-A3 immunotherapeutic in the equivalent adju-
vant settings used for cohorts 2 and 3 did not increase disease-
free survival. However, the MAGRIT trial was not designed 
to evaluate cell-mediated immunity. In cohorts 2 and 3 in this 
study, 4 out of 18 and 6 out of 18 patients had relapsed by the 
concluding visit, respectively, whereas in cohort 1, no patients 
had relapsed. Moreover, cohorts 1 and 2 contained more 
patients with stages II and III tumors than cohort 3. However, 
given the limitation of the study design, further investiga-
tions would be required to evaluate whether the concurrent 
administration of chemotherapy with immunotherapy resulted 
in better clinical outcomes. Also given the recent results of 
MAGRIT and the trials evaluating immune-checkpoint inhibi-
tors, the induction of tumor-specific immune responses may 
be insufficient for improving clinical outcomes in the absence 
FIGURE 3.  MAGE-A3-specific immunogenicity in the total treated population (TTP). A, Geometric mean MAGE-A3-specific 
antibody concentrations in each cohort, measured in serum samples taken before the first dose (at week 0) of the MAGE-A3 
immunotherapeutic through week 30. Gray triangles on the x-axis indicate the timings of each of the eight MAGE-A3 immuno-
therapeutic doses. Error bars describe 95% confidence intervals (95% CIs). At weeks 0, 7, 13, 16, 19, 22, and 27; N = 19, 12, 
15, 15, 15, 15, and 15 in cohort 1, respectively; N = 18, 17, 15, 16, 14, 12, and 13 in cohort 2, respectively; and N = 17, 14, 
12, 11, 11, 9, and 9, in cohort 3, and N = 12, 10, 9, 8, 8, 8 and 7, in cohort 4, respectively. At week 6 in cohort 1, N = 13. B, 
MAGE-A3-specific ratios of CD4+ T-cell immunogenicity scores (based on the frequencies of interferon (IFN)-γ+ tumor necrosis 
factor (TNF)-α+ CD4+ T cells in peptide-stimulation cultures of peripheral blood mononuclear cells [PBMCs] in vitro) for indi-
vidual patients in each cohort, typically calculated as the higher of the two T-cell immunogenicity scores posttreatment divided 
by the T-cell immunogenicity score pretreatment. The postimmunotherapy scores were evaluated 3 weeks postdose 4 or 5 
weeks postdose 8, except for two patients in cohort 1 and one patient in cohort 4. In these patients, the scores were evaluated 
in PBMC samples taken before the patients’ early discontinuation (at least after dose 1). Bars in gray or white describe ratios for 
samples in which posttreatment MAGE-A3-specific T-cell responses were or were not identified (i.e., T-cell immunogenicity score 
was above or below the cutoff), respectively. A MAGE-A3-specific CD4+ T-cell response to immunotherapy was induced if the 
T-cell immunogenicity score posttreatment was above the cutoff and was greater than or equal to fourfold higher (dotted line) 
than the T-cell immunogenicity score pretreatment. Cohort 1, concurrent chemotherapy + immunotherapy; cohort 2, sequen-
tial chemotherapy then immunotherapy; cohort 3, immunotherapy only; cohort 4 (unresectable non–small-cell lung cancer), 
sequential chemotherapy, radiotherapy, then immunotherapy.
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of releasing the immune blockade.24–28 Nevertheless, this 
study demonstrated that administering active immunotherapy 
and chemotherapy together is feasible. The earlier develop-
ment of a tumor-specific immune response should be advanta-
geous in a disease setting where relapse tends to be relatively 
rapid postsurgery.
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